Dataset Papers in PharmacologyVolume 2013 (2013), Article ID 698435, 14 pageshttp://dx.doi.org/10.7167/2013/698435

Dataset Paper

Alterations of Hormone-Sensitive Adenylyl Cyclase System in the Tissues of Rats with Long-Term Streptozotocin Diabetes and the Influence of Intranasal Insulin

Alexander O. Shpakov, Kira V. Derkach, Irina V. Moyseyuk, and Oksana V. Chistyakova

Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Thorez Avenue 44, St. Petersburg 194223, Russia

Received 31 May 2012; Accepted 19 July 2012

Academic Editors: T. H.-W. Huang, Y. Huang, W.-L. Lu, and Y. Uezono

Copyright © 2013 Alexander O. Shpakov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

One of the causes of complications in type 1 diabetes mellitus (T1DM) is the changes in adenylyl cyclase (AC) signaling system, identified on the early stages of the disease. However, the most significant disturbances in this system occur on the later stages of T1DM, which ultimately leads to severe complications, but functional state of the AC system in late T1DM is poorly understood. The aim of this work was to study alterations in AC system sensitive to biogenic amines and polypeptide hormones in the heart, brain, and testes of male rats with long-term, 7-month, streptozotocin T1DM and to assess the influence on them of 135-day therapy with intranasal insulin. It was shown that AC effects of -adrenergic agonists in the heart, serotonin receptor agonists and PACAP-38 in the brain, chorionic gonadotropin and PACAP-38 in the testes, and somatostatin in all investigated tissues in long-term T1DM were drastically decreased. The treatment with intranasal insulin (0.48 IU/day) significantly restored these effects. The results were obtained suggesting that long-term T1DM induces significant alterations in hormone-sensitive AC system in the heart, brain, and testes that are much more pronounced, compared with short-term T1DM, and include a large number of hormonal regulations.

1. Introduction

The type 1 diabetes mellitus (T1DM), one of the most severe metabolic disorders in humans, characterized by hyperglycemia due to a relative or an absolute lack of insulin, leads to many complications, such as coronary heart diseases, hypertension, atherosclerosis, neurodegenerative diseases, cognitive deficit, and dysfunctions of the reproductive system [1, 2]. One of the causes of these complications is the alterations in hormone-sensitive signaling systems, the adenylyl cyclase (AC) system in particular [3, 4]. It was shown that changes in the functional activity of AC system in the heart, brain, and reproductive tissues in experimental T1DM were tissue and hormone specific [5–10]. Generally, the effects of hormones acting on AC via G proteins of the inhibitory type () were changed to a greater degree compared with those realized via G proteins of the stimulating type (), likely due to a decrease of proteins expression and a reduction of their functional activity and coupling with upstream and downstream signal proteins.

The degree of alterations and abnormalities in hormonal signaling systems is well correlated with the severity of T1DM and its complications [11, 12]. As a result, at the later stages of the disease characterized by pronounced clinical symptoms, there are all reasons to expect the changes in these systems to be much expressed. However, the functional state of hormonal signaling systems in late T1DM has been studied rather poorly yet, which greatly complicates the treatment of this disease and the monitoring of diabetic patients. The aim of this work was to identify and study the alterations in AC system sensitive to biogenic amines and polypeptide hormones in the heart, brain, and testes of male rats with long-term, 7-month, streptozotocin (STZ) T1DM and to reveal the influence of 135-day therapy with intranasal insulin (I-I) on the functioning and sensitivity of this system to hormones. The intranasal route of insulin delivery was chosen proceeding from the fact that I-I has no significant influence on the level of peripheral glucose and, therefore, does not provoke hypoglycemic episodes [13, 14]. I-I normalizes metabolic processes and improves cognitive functions, but the molecular mechanisms and targets of its action have not been well defined [15, 16]. It should be noted also that the information concerning the influence of I-I on human and experimental T1DM is scarce [17, 18].

2. Methodology

The model of long-term streptozotocin T1DM in adult male rats and the intranasal insulin treatment were as follows. For experiments, adult male Wistar rats housed in plastic sawdust-covered cages with a normal light-dark cycle and free access to food and water were obtained. The experiments were carried out under the Bioethics Committee of Sechenov Institute of Evolutionary Physiology and Biochemistry, St. Petersburg, Russia (Institutional Guidelines, December 23, 2010) and “Guidelines for the treatment of animals in behavior research and teaching” [19]. All efforts were made to minimize animal suffering and reduce the number of animals used.

After a one-week adaptation period, rats aged 17-18 weeks were randomly divided into diabetic and control groups. Experimental diabetes mellitus of the type 1 (T1DM) was induced by a three consecutive intraperitoneal injection of freshly prepared STZ (Sigma, St. Louis, Mo, USA) in 0.1 M citrate buffer (pH 4.5) on the first, tenth, and eightieth days of experiments at doses 40, 35, and 30 mg/kg of body weight, respectively. Daily serum glucose level was assessed using test strips One Touch Ultra (USA) and a glucometer (LifeScan Johnson & Johnson, Denmark) via puncture of the tail. Nine days after each STZ administration, animals with fasting blood glucose level over 12 mM were considered diabetic and were used in further experiments. Diabetic rats had, in addition, a very pronounced glucosuria. The monitoring of glucose concentration in the urine was carried out using test strips (Combi-Screen Analyticon, Germany). The insulin concentration in rat serum was determined using Rat Insulin ELISA (Mercodia AB, Sweden).

At the seventy-fifth day of experiment, 5 days before the last injection of STZ, diabetic rats were divided into two equal groups. One group of diabetic rats (Group DI) was treated with I-I and the other with citrate buffer without insulin (Group D). Control animals were also divided into two equal groups: one received I-I (Group CI) and the other buffer without it (Group C). Intranasal delivery of insulin to the rat brain was performed as described previously by Thorne and coworkers [20]. Crystalline insulin at concentration 24 IU/mL was dissolved in 0.1 M citrate buffer, pH 4.5, and administered intranasally to both diabetic (Group DI) and control (Group CI) rats once a day. Each rat was placed in a supine position and then an average of 20 µL of insulin solution (0.48 IU) was administered by Eppendorf pipette as 5 µL drops in each nostril, in turn, every 1-2 min. Control animals were given the equal volume of saline, pH 4.5. The I-I treatment of rats from Groups DI and CI was carried out during 135 days. Twenty-four hours after the last intranasal administration of insulin or saline (on the 210th day of the experiment), the animals were decapitated under anesthetics, and their heart, brain tissues (cerebral cortex, striatum, hypothalamus, and olfactory bulbs), and testes were rapidly dissected and frozen on dry ice. Finally, four groups of rats were investigated: control animals (Group C, ), control animals treated with I-I (Group CI, ), diabetic animals with 210-day streptozotocin-induced diabetes mellitus of the type 1 (T1DM) (Group D, ), and diabetic animals treated with I-I (Group DI, ).

The chemicals used in the study were purchased from Sigma-Aldrich (St. Louis, MO, USA) and Calbiochem (San Diego, CA, USA). STZ, ,-imidoguanosine-5′-triphosphate (GppNHp), forskolin, human chorionic gonadotropin (hCG), somatostatin-14, pituitary adenylyl cyclase-activating peptide-38 (PACAP-38), serotonin, noradrenaline, isoproterenol, dopamine, and bromocriptine were purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-nonyloxytryptamine and 5-chloro-2-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (EMD-386088) were purchased from Tocris Cookson Ltd. (UK). []-ATP (4 Ci/mmol) was purchased from Isotope Company (St. Petersburg, Russia).

To study the functional activity of hormone-sensitive AC system in long-term T1DM, we chose the hormones that regulate AC activity via -coupled (stimulation) and -coupled receptors (inhibition) and play a key role in the functioning of the cardiovascular, nervous, and reproductive systems. The brain serotonin-regulated AC system was examined using 5-nonyloxytryptamine, a selective agonist of -coupled 5-hydroxytryptamine receptors (5-HTRs) of the subtype 1B (5-HT1BR); EMD-386088, a selective agonist of -coupled 5-HT₆R; and the brain dopamine-regulated AC system using nonselective dopamine and bromocriptine, a selective agonist of D₂-dopamine receptors (D₂-DARs). In all investigated tissues, the AC inhibiting the effect of somatostatin realized via -coupled somatostatin receptors was studied. The myocardial adrenergic signaling was studied using noradrenaline, an agonist of - and -adrenergic receptors (-AR and -AR), and isoproterenol, a nonselective -AR agonist, and in the testes using hCG, a glycoprotein hormone produced during pregnancy, and PACAP-38 that stimulate AC via -coupled luteinizing hormone/hCG and PAC1 receptors, respectively.

The preparation of cardiac membranes from the rat heart was performed according to Baker and Potter [21], with some modifications. The dissected hearts were placed in ice-cold 0.9% NaCl, and atria, fat, and valves were removed. The tissues were cut into small pieces; homogenized with a Polytron in 20 volumes of ice-cold 40 mM Tris-HCl buffer (pH 7.4) containing 5 mM MgCl₂, 320 mM sucrose, and a cocktail of protease inhibitors 500 µM O-fenantrolin, 2 µM pepstatin, and 1 mM phenylmethylsulfonyl fluoride (Buffer A); and centrifuged at 480 ×g for 10 min at 4°C. The pellet was discarded, and the supernatant was centrifuged at 27 500 ×g for 20 min at 4°C. The pellet was resuspended in Buffer A (without sucrose) and then centrifuged at 27 500 ×g for 20 min. The preparation of synaptosomal membranes from the rat brain was performed as described earlier [22]. The brain tissues were dissected on ice and homogenized with a Polytron in 30 volumes of ice-cold 50 mM Tris-HCl buffer (pH 7.4) containing 10 mM MgCl₂, 2 mM EGTA, 10% (w/v) sucrose, and a cocktail of protease inhibitors (Buffer B). The obtained material underwent centrifuge procedures, each performed at 4°C. The crude homogenate was centrifuged at 1000 ×g for 10 min; the resulting pellet was discarded and the supernatant was centrifuged at 9000 ×g for 20 min. The pellet was resuspended in Buffer B (without sucrose) and centrifuged at 35 000 ×g for 10 min. The isolation of plasma membranes from testes was carried out as described earlier [23]. The testes were placed in ice-cold Buffer A and homogenized with a Polytron. The homogenate was centrifuged at 1500 ×g for 10 min at 4°C. The supernatant was centrifuged at 20 000 ×g for 30 min at 4°C. The resulting pellet was washed in 10 volumes of Buffer A (without sucrose) and centrifuged again at 20 000 ×g for 30 min. The final pellet was resuspended in the 50 mM Tris-HCl buffer (pH 7.4) to produce the membrane fraction with a protein concentration range 1–3 mg/mL and stored at −70°C. The protein concentration of each membrane preparation in all experiments was measured by the method of Lowry and colleagues using BSA as a standard.

The adenylyl cyclase (AC, EC 4.6.1.1) activity was measured as described previously [22]. The reaction mixture (final volume 50 µL) contained 50 mM Tris-HCl (pH 7.5), 5 mM MgCl₂, 1 mM ATP, 1 µCi []-ATP, 0.1 mM cAMP, 20 mM creatine phosphate, 0.2 mg/mL creatine phosphokinase, and 15–45 µg of membrane protein. Incubation was carried out at 37°C for 10 min. The reaction was initiated by the addition of membrane protein and terminated by the addition of 100 µL of 0.5 M HCl, followed by immersing the tubes with mixture in a boiling water bath for 6 min; 100 µL of 1.5 M imidazole was added to each tube. In these conditions, the AC activity was linear. []-cAMP formed as a result of the enzyme reactions was separated using alumina for column chromatography. The samples were placed on neutral alumina columns, and cAMP was eluted with 10 mL of 10 mM imidazole-HCl buffer (pH 7.4). The eluates were collected in scintillation vials and counted using an LS 6500 scintillation counter (Beckman Instruments Inc., USA). Each assay was carried out in triplicate at least three times, and the results were expressed as picomole (pmol) cAMP/min per milligram (mg) of membrane protein. The basal activity was measured in the absence of hormones and forskolin. To measure AC inhibition by hormones, the enzyme was activated by forskolin ( M).

The data are presented as the weighted mean ± weighted standard deviation. The difference in the weight and in glucose and insulin plasma levels of control and diabetic animals and in the basal activity of AC in the tissue membrane fractions of control and diabetic animals as well as the difference in the AC activity in the membrane fractions treated by hormones and nonhormonal AC regulators (GppNHp and forskolin) in each case was statistically assessed using the one-way analysis of variance (ANOVA, t-test) and was considered significant at . The assumption of normality was assessed using Shapiro-Wilk test. The results of the test confirmed that the obtained data are a sample from a normal distribution at .

3. Dataset Description

The dataset associated with this Dataset Paper consists of 8 items, which are described as follows.

Dataset Item 1 (Table). Body weight, plasma glucose, and plasma insulin levels in control rats without (Group C) and with (Group CI) I-I treatment and in rats with long-term, 7-month, STZ T1DM without (Group D) and with (Group DI) I-I treatment. The plasma glucose level in diabetic rats was considerably increased during the whole period after the first treatment with STZ due to insulin deficiency, and their body weight was significantly lower as compared with control. In rats with 7-month STZ T1DM, glucose levels were approximately three times higher and the weight was reduced by 14% compared with the respective control (Table 1). In diabetic rats, the therapy with I-I led to an increase of the body weight and to a decrease of the elevated glucose level but had no effect on insulin deficit. In control animals, I-I changed neither body weight nor glucose level and decreased a little insulin level.

Column 1: Group Name

Column 2: Body Weight (g)

Column 3: Plasma Glucose (mM)

Column 4: Plasma Insulin (ng mL⁻¹)

Dataset Item 2 (Table). The basal AC activity in plasma membrane fractions isolated from the heart, brain, and testes of insulin-treated and -untreated diabetic and control rats (in picomole (pmol) cAMP/min per milligram (mg) of membrane protein). Group C is the control animals (); CI, the control animals treated with intranasal insulin (I-I) (); D, the diabetic animals with 210-day streptozotocin-induced diabetes mellitus of the type 1 (T1DM) (); DI, the diabetic animals treated with I-I (). The basal AC activity in the heart and testes of diabetic rats, compared with control, was significantly decreased (Table 2). The treatment with I-I did not influence on the basal AC activity in the heart and testes of control animals but restored it in diabetic rats. In the brain of diabetic rats, the basal AC activity did not change considerably compared with control, and I-I had little effect on it in both control and diabetic animals. This indicates weakening of catalytic function of AC in the diabetic heart and testes, but not in the brain.

Column 1: Group Name

Column 2: Series

Column 3: Heart

Column 4: Brain

Column 5: Testes

Dataset Item 3 (Table). AC stimulating effects of GppNHp activating proteins directly interacting with catalytic site of AC in the tissues of diabetic and nondiabetic rats. Group C is the control animals (); CI, the control animals treated with intranasal insulin (I-I) (); D, the diabetic animals with 210-day streptozotocin-induced diabetes mellitus of the type 1 (T1DM) (); DI, the diabetic animals treated with I-I (). In the heart, brain, and testes of control rats, AC stimulating effects of GppNHp ( M), nonhydrolysable analog of GTP, were 229, 204, and 105% over the basal activity of the enzyme, respectively. It is a common knowledge that GppNHp activates proteins and thus stimulates the basal AC activity. In the diabetic heart and testes, AC effects of GppNHp were decreased, most significantly in the testes, and I-I restored the effects of GppNHp in the heart but did not in the testes (Figure 1(a) and Table 3(a)). In the diabetic brain, the AC effect of GppNHp decreased insignificantly. These data indicate the attenuation of catalytic function of the membrane-bound AC in the heart and testes of rats with long-term T1DM, whereas in the diabetic brain the enzyme catalytic properties were not altered. Note that in the short-term T1DM, we found no significant changes in the basal and GppNHp-stimulated AC activities in the heart and a small decrease of these activities in the testes [10, 25].

Column 1: Group Name

Column 2: Series

Column 3: Heart

Column 4: Brain

Column 5: Testes

Dataset Item 4 (Table). AC stimulating effects of forskolin directly interacting with catalytic site of AC in the tissues of diabetic and nondiabetic rats. Group C is the control animals (); CI, the control animals treated with intranasal insulin (I-I) (); D, the diabetic animals with 210-day streptozotocin-induced diabetes mellitus of the type 1 (T1DM) (); DI, the diabetic animals treated with I-I (). In the heart, brain, and testes of control rats, AC stimulating effects of diterpene forskolin ( M) were 661, 619, and 205%, respectively. It is a common knowledge that forskolin directly interacts with catalytic site of the enzyme. In the diabetic heart and testes, AC effects of forskolin were decreased, most significantly in the testes, and I-I restored the effects of forskolin in the heart but did not in the testes (Figure 1(b) and Table 3(b)). In the diabetic brain, the AC effect of forskolin did not change. These data indicate the attenuation of catalytic function of the membrane-bound AC in the heart and testes of rats with long-term T1DM, whereas in the diabetic brain, the enzyme catalytic properties were not altered. Note that in the short-term T1DM, we found no significant changes in the basal and forskolin-stimulated AC activities in the heart and a small decrease of these activities in the testes [10, 25].

Column 1: Group Name

Column 2: Series

Column 3: Heart

Column 4: Brain

Column 5: Testes

Dataset Item 5 (Table). The AC effects of hormones activating the enzyme via protein-coupled receptors in the tissues of diabetic rats and under the influence of I-I. In the diabetic heart, the AC stimulating effects of isoproterenol and noradrenaline, the agonists of -adrenergic receptors (-AR), were decreased and partially restored by I-I. A most significant decrease was observed with noradrenaline acting preferably via -AR undergoing considerable down-regulation in T1DM [26], whereas AC effect of isoproterenol, nonselective -AR agonist, was reduced to a lesser extent (Figure 2(a) and Table 4(a)). In our view, this may be due to the fact that the signaling pathways mediated via -AR, the main target of isoproterenol, in the heart of rats with T1DM, even short-term, were preserved or enhanced, this being a compensatory mechanism triggered by reducing the functional activity of -AR [11, 27]. Thus, in the heart of 14-week STZ rats, the content of -AR protein as well as -AR mRNA was decreased to 35 and 45%, respectively, and the decrease of maximal chronotropic response to selective -AR agonists was 70% of that in control, whereas the number of -AR and the chronotropic response to selective -AR agonist fenoterol did not change [27].

Column 1: Group Name

Column 2: Series

Column 3: Isoproterenol

Column 4: Noradrenaline

Dataset Item 6 (Table). In the diabetic brain, the AC effects of isoproterenol, serotonin, selective 5-HT₆R agonist EMD-386088, and PACAP-38 were significantly decreased, but the corresponding effect of dopamine did not change (Figure 2(b) and Table 4(b)). The decreased AC effects of hormones were completely (PACAP-38, EMD-386088) or partially (isoproterenol, serotonin) restored by I-I treatment. A decrease of the AC effect of EMD-386088 indicates the impairment of 5-HT₆R-mediated pathways in the diabetic brain but does not exclude attenuation of the functional activity of the other types of 5-HTR that are also coupled with AC via proteins. As we showed earlier, in the model of short-term T1DM and the neonatal model of type 2 diabetes mellitus (T2DM), although the stimulating effects of serotonin on AC activity and GTP binding of proteins in the diabetic brain were reduced, the corresponding effects of EMD-386088 and, as a result, 5-HT₆R-mediated AC signaling did not change [16, 25]. There was a decrease in the number of 5-HT₆R and a reduced AC response to selective 5-HT₆R agonists in the brain of patients with prolonged Alzheimer's disease due to the neurodegenerative alterations in neuronal and glial cells [28]. The decrease in the sensitivity of AC to -AR-agonist isoproterenol points to a weakening of -AR signaling in the diabetic brain, which negatively influences the synaptic transmission provoked by impairment of the mechanism involving increase of intracellular cAMP concentration and protein synthesis [29] and induces disturbances in the cerebral microvessels, whose functions are controlled via different signaling systems, the adrenergic in particular [30]. A significant reduction of AC effect of PACAP-38 having an important role in protection of neuronal cells from damage and neurodegenerative changes [31] speaks in favor of abnormalities in PACAP-mediated neuroprotection in the case of long-term T1DM. It has been noticed that short-term T1DM and neonatal T2DM had no effect on the regulation of brain AC activity and protein binding by PACAP-38 [16, 25]. We showed that the 135-day therapy with I-I prevents the decline of AC stimulation induced by PACAP-38 in the diabetic brain. Thus, the ability of I-I to restore AC signaling pathways regulated by PACAP-38 and some biogenic amines may be one of the main mechanisms of positive influence of I-I on the impaired CNS functions in human and experimental DM [16, 24, 32]. The AC effect of dopamine, contrary to the other investigated hormones, did not change in the diabetic brain. Earlier it was shown that dopamine-stimulated cAMP production in the brain of rats with 14-week alloxan DM or neonatal T2DM was markedly increased [16, 33]. This may be due to a compensatory increase in the expression of protein-coupled D₁-DAR, as in the case of short-term STZ T1DM [34].

Column 1: Group Name

Column 2: Series

Column 3: Isoproterenol

Column 4: Serotonin

Column 5: EMD-386088

Column 6: Dopamine

Column 7: PACAP-38

Dataset Item 7 (Table). In the diabetic testes, the AC effects of hCG, structural and functional homologue of luteinizing hormone, and PACAP-38 were decreased significantly, and the effect of hCG was partially restored by I-I treatment (Figure 2(c) and Table 4(c)). The reduction in hCG- and PACAP-induced AC stimulation in the rat testes in long-term T1DM was more pronounced compared with that in short-term T1DM [10]. These results indicate that the abnormalities in testicular function in human and experimental T1DM can be ascribed to the changes in sensitivity of AC to gonadotropins and peptide hormones belonging to the vasoactive intestinal peptide/PACAP family. It should be mentioned that AC stimulation induced by vasoactive intestinal peptide in the seminal vesicle of rats with STZ T1DM was considerably reduced, which was associated with a decrease of subunit level [35, 36].

Column 1: Group Name

Column 2: Series

Column 3: hCG

Column 4: PACAP-38

Dataset Item 8 (Table). The AC inhibitory effects of hormones acting via protein-coupled receptors in the tissues of diabetic and nondiabetic rats, which were estimated by the influence of the hormones on forskolin-stimulated AC activity. AC inhibitory effects of somatostatin in all the investigated tissues, noradrenaline in the heart, and 5-HT1B/1DR agonist 5-nonyloxytryptamine in the brain were decreased significantly in T1DM compared with control (Figure 3 and Table 5). The corresponding effects of noradrenaline and D₂-DAR agonist bromocriptine in the diabetic brain changed, but not very much. The therapy with I-I restored the inhibitory effects of noradrenaline in the heart and of 5-nonyloxytryptamine in the brain but influenced only a little the somatostatin effects in all the studied tissues. The significant decrease of AC effect of 5-nonyloxytryptamine indicates attenuation of 5-HT₁R-mediated AC signaling in the brain in the model of prolonged T1DM. These findings are consistent with the data obtained by the other authors on the weakening of the behavioral response of rats with T1DM to 5-HT1AR agonist 8-hydroxy-2-(dipropylamino) tetralin hydrobromide [37], and with our data concerning a decrease of regulatory effects of 5-nonyloxytryptamine on AC activity and proteins GTP binding in the brain of rats with neonatal T2DM [16]. The abnormalities in 5-HT₁R-mediated signaling pathways are able to induce the impairment of memory and cognitive functions and psychic disorders [38]. The decrease of AC inhibitory effects of noradrenaline in the diabetic heart indicates alterations in cardiac signaling including -coupled -AR, which may be caused by a decrease in the number of -AR and by a reduction of expression and functional activity of proteins in the heart of rats with T1DM [5, 6]. As shown in our previous studies, the changes in -AR signaling can be identified at the early stages of STZ T1DM, being, however, less expressed compared with the later stages [8, 25]. The most dramatic changes were revealed in AC signaling cascades regulated by somatostatin. Somatostatin-induced AC inhibition was significantly reduced in all tissues under study, and this decline surpassed that in short-term STZ T1DM and neonatal T2DM [16, 25]. These data are the evidence for the degree of damage in somatostatin-regulated AC system enhanced with increasing duration and severity of the diabetic state. The reports are available describing the decrease of expression of some types of somatostatin receptors in the hypothalamus and pituitary in rats with T1DM [39]. In the atria of 4-week STZ rats, the suppressive effect of somatostatin on ANP secretion, realized via -coupled sst2-somatostatin receptor, and the level of mRNA and protein content for this receptor was markedly decreased [40]. In the glucagon cells isolated from the pancreatic islets from patients with T2DM, there were found no sst1- and sst4-somatostatin receptors, and in the somatostatin cells, no sst1-, sst2-, sst3-, and sst-4-somatostatin receptors were detected [41]. This gave grounds for a suggestion that the decrease of the level and the function of somatostatin receptors in patients with T2DM and animals with T1DM may be due to the elevated level of circulating somatostatin inducing downregulation of the cognate receptors [42]. Taking into consideration the importance and complexity of the physiological and biochemical effects of somatostatin and its involvement in the pathogenesis of a variety of diseases, it would be right to say that the disturbances in somatostatin-regulated AC system are likely to be responsible for the development of T1DM-associated dysfunctions in the cardiovascular, nervous, and reproductive systems. This indicates the attenuation of protein-coupled signaling cascades, especially somatostatin-regulated, in the heart, brain, and testes of rats with long-term STZ T1DM, and the partial restoration of these cascades with I-I treatment.

Column 1: Group Name

Column 2: Series

Column 3: Hormone

Column 4: Heart

Column 5: Percentage in Heart

Column 6: Brain

Column 7: Percentage in Brain

Column 8: Testes

Column 9: Percentage in Testes

4. Concluding Remarks

The study of the model of long-term T1DM is very important for understanding the molecular mechanisms responsible for the development of complications of this disease and for finding the approaches to their therapy and diagnostics. We showed that in 7-month STZ T1DM the regulatory effects of a large number of hormones including both AC activators, such as ligands of -AR and 5-HT₆R, PACAP-38, and gonadotropin, and AC inhibitors, such as noradrenaline, somatostatin, and selective agonist of 5-HT1B/1DR, change significantly. The alterations in AC signaling may be regarded as a result of disturbances in the fundamental cellular processes in the tissues and organs of diabetic individuals and also as a mechanism compensating for the impairment of insulin-mediated signaling provoked by prolonged insulin deficiency. The alterations in AC signaling we revealed in long-term T1DM are expressed much better compared with short-term T1DM studied in detail by us and the other authors earlier and cover a wide spectrum of hormonal regulations [5, 8–11]. A prolonged, 135-day, treatment of diabetic rats with I-I resulted in restoration of the sensitivity of the cardiac AC system to nonhormonal regulators (GppNHp, forskolin) and adrenergic agonists of the brain AC system to selective agonists of 5-HTR and PACAP-38 and of the testicular AC system to hCG. Our results give strong evidence for the benefit of I-I in the therapy of diabetic patients with prolonged T1DM aimed at improving functioning of the cardiovascular, nervous, and reproductive systems and preventing their impairments; they indicate that insulin signaling system, the key component of overall hormonal network in the brain, is an important target in the treatment of severe forms of T1DM. The increase in sensitivity of cardiac AC to adrenergic ligands and testicular AC to gonadotropin in diabetic rats receiving I-I suggests that intranasaly adminestered hormone acts on the cardiovascular system and on the testes, a distal component of the hypothalamic-pituitary-gonadal axis, via the central mechanisms due to the impovement of brain signaling impaired in long-term T1DM.

Table 1: Body weight, plasma glucose, and plasma insulin levels in control rats without (Group C) and with (Group CI) I-I treatment and in rats with long-term, 7-month, STZ T1DM without (Group D) and with (Group DI) I-I treatment.

Groups of Rats
Body Weight (g)
Plasma Glucose (mM)
Plasma Insulin (ng mL⁻¹)

Group C (n = 8)
412 ± 27 (C-D, P = 0.0018; C-CI, P = 0.3835)
4.9 ± 0.5(C-D, P = 0.0003; C-CI, P = 0.9913)
2.2 ± 0.3(C-D, P = 10⁻⁹; C-CI, P = 0.0017)

Group CI (n = 7)
428 ± 39(CI-DI, P = 0.0234)
4.9 ± 0.7(CI-DI, P = 0.0164)
1.5 ± 0.4(CI-DI, P = 0.00008)

Group D (n = 8)
354 ± 32(D-DI, P = 0.1497)
16.7 ± 5.0(D-DI, P = 0.0458)
0.3 ± 0.2(D-DI, P = 0.8523)

Group DI (n = 7)
379 ± 30
11.0 ± 4.9
0.4 ± 0.2

Values are expressed as the mean ± standard deviation.

Table 2: The basal AC activity in plasma membrane fractions isolated from the heart, brain, and testes of insulin-treated and -untreated diabetic and control rats (in pmol cAMP/min per mg of membrane protein). C: control animals; CI: control animals treated with intranasal insulin (I-I); D: diabetic animals with 210-day streptozotocin-induced diabetes mellitus of the type 1 (T1DM); DI: diabetic animals treated with I-I.

Groups of Rats
Heart
Brain
Testes

Group C (n = 8)
30.4 ± 0.3(C-D, P = 0.00000147; C-CI, P = 0.1433)
26.8 ± 0.5(C-D, P = 0.0056; C-CI, P = 0.3619)
20.0 ± 0.2(C-D, P = 10⁻¹³; C-CI, P = 0.1685)

Average of the first series
30.5
29.0
18.1

Average of the second series
26.6
28.8
18.8

Average of the third series
27.3
25.6
21.0

Average of the fourth series
31.0
25.3
18.2

Group CI (n = 7)
28.9 ± 0.3(CI-DI, P = 0.0003)
23.8 ± 0.7(CI-DI, P = 0.7917)
18.2 ± 0.2(CI-DI, P = 10⁻⁷)

Average of the first series
31.1
25.7
16.0

Average of the second series
32.0
23.4
19.4

Average of the third series
26.3
22.1
19.5

Average of the fourth series
32.2
32.2
17.8

Group D (n = 8)
23.9 ± 0.5(D-DI, P = 0.0012)
25.1 ± 0.2(D-DI, P = 0.2915)
11.1 ± 0.3(D-DI, P = 0.0001)

Average of the first series
21.5
25.8
10.1

Average of the second series
24.8
25.5
11.4

Average of the third series
24.2
24.7
10.6

Average of the fourth series
21.6
24.6
12.4

Group DI (n = 7)
26.8 ± 0.2
25.5 ± 1.3
12.4 ± 0.2

Average of the first series
28.9
23.9
11.5

Average of the second series
25.3
29.2
13.7

Average of the third series
24.4
25.1
13.9

Average of the fourth series
26.0
27.0
14.6

Values are expressed as the weighted mean ± weighted standard deviation of four individual experiments.

Table 3: The stimulating effects of GppNHp (a) and forskolin (b) on the basal AC activity in the heart, brain, and testes in diabetic and control rats treated with I-I or saline. C: control animals; CI: control animals treated with intranasal insulin (I-I); D: diabetic animals with 210-day streptozotocin-induced diabetes mellitus of the type 1 (T1DM); DI: diabetic animals treated with I-I. GppNHp and forskolin were taken at 10⁻⁵ M. Values are the weighted mean ± weighted standard deviation of three individual experiments, each performed in triplicate.

(a)  

Groups of Rats
Heart
Brain
Testes

Group C (n = 8)
69.6 ± 1.7(C-D, P = 10⁻⁹;C-CI, P = 0.3460)
54.6 ± 0.6(C-D, P = 0.0322;C-CI, P = 0.2613)
20.9 ± 0.3(C-D, P = 10⁻⁶;C-CI, P = 0.3268)

Average of the first series
68.0
63.5
20.1

Average of the second series
67.8
54.3
26.4

Average of the third series
74.7
52.6
23.8

Group CI (n = 7)
66.8 ± 1.0(CI-DI, P = 0.0040)
54.0 ± 2.4(CI-DI, P = 0.2172)
24.4 ± 1.0(CI-DI, P = 10⁻¹⁰)

Average of the first series
75.0
59.8
23.8

Average of the second series
63.1
45.4
24.9

Average of the third series
64.6
54.2
25.4

Group D (n = 8)
43.2 ± 1.1(D-DI, P = 10⁻⁷)
50.6 ± 1.5(D-DI, P = 0.4860)
9.0 ± 0.2(D-DI, P = 0.3766)

Average of the first series
42.0
56.0
9.0

Average of the second series
49.1
47.7
8.6

Average of the third series
42.4
48.9
9.8

Group DI (n = 7)
59.7 ± 1.2
47.5 ± 2.0
8.5 ± 0.3

Average of the first series
56.7
53.3
8.5

Average of the second series
57.5
41.9
9.6

Average of the third series
62.1
51.9
8.3

(b)  

Groups of Rats
Heart
Brain
Testes

Group C (n = 8)
201 ± 4(C-D, P = 10⁻⁸;C-CI, P = 0.1781)
166 ± 4(C-D, P = 0.3585;C-CI, P = 0.2458)
41 ± 2(C-D, P = 10⁻⁹;C-CI, P = 0.3261)

Average of the first series
191
145
40

Average of the second series
204
173
42

Average of the third series
212
156
46

Group CI (n = 7)
203 ± 7(CI-DI, P = 0.0211)
164 ± 3(CI-DI, P = 0.0033)
38 ± 2(CI-DI, P = 10⁻⁶)

Average of the first series
173
178
44

Average of the second series
189
159
35

Average of the third series
209
158
41

Group D (n = 8)
145 ± 3(D-DI, P = 0.0004)
152 ± 7(D-DI, P = 0.5864)
18 ± 1(D-DI, P = 0.2506)

Average of the first series
131
175
14

Average of the second series
155
138
23

Average of the third series
153
136
21

Group DI (n = 7)
166 ± 2
153 ± 3
23 ± 2

Average of the first series
171
161
27

Average of the second series
176
139
21

Average of the third series
162
135
18

Table 4: The stimulating effects of hormones on AC activity in (a) the heart, (b) brain, and (c) testes of diabetic and control rats with and without therapy by I-I. C: control animals; CI: control animals treated with intranasal insulin (I-I); D: diabetic animals with 210-day streptozotocin-induced diabetes mellitus of the type 1 (T1DM); DI: diabetic animals treated with I-I. Isoproterenol, noradrenaline, serotonin, EMD-386088, and dopamine were taken at 10⁻⁵ M, PACAP-38 at 10⁻⁷ M, and hCG at 10⁻⁸ M. Values are the weighted mean ± weighted standard deviation of three individual experiments, each performed in triplicate.

(a) In picomole (pmol) of cAMP/min per milligram (mg) of membrane protein

Groups of Rats
Isoproterenol
Noradrenaline

Group C (n = 8)
65.0 ± 2.7(C-D,P = 0.0004;C-CI, P = 0.1348)
47.2 ± 1.1(C-D,P = 10⁻⁸;C-CI,P = 0.4434)

Average of the first series
73.7
53.6

Average of the second series
54.9
48.1

Average of the third series
66.6
46.0

Group CI (n = 7)
60.3 ± 0.9(CI-DI, P = 0.2191)
52.7 ± 1.9(CI-DI, P = 0.1188)

Average of the first series
61.6
42.6

Average of the second series
61.1
56.7

Average of the third series
57.3
55.0

Group D (n = 8)
47.0 ± 1.8(D-DI, P = 0.0032)
29.5 ± 1.6(D-DI, P = 0.0025)

Average of the first series
43.9
30.3

Average of the second series
44.4
32.3

Average of the third series
55.2
25.8

Group DI (n = 7)
56.2 ± 1.7
37.9 ± 2.3

Average of the first series
53.8
31.9

Average of the second series
56.1
51.4

Average of the third series
62.0
49.8

(b) In picomole (pmol) of cAMP/min per milligram (mg) of membrane protein

Groups of Rats
Isoproterenol
Serotonin
EMD-386088
Dopamine
PACAP-38

Group C (n = 8)
42.6 ± 1.1(C-D, P = 10⁻⁹;C-CI,P = 0.0374)
81.3 ± 2.2(C-D, P = 0.0066;C-CI, P = 0.7467)
28.3 ± 1.8(C-D, P = 0.0004;C-CI, P = 0.3930)
52.2 ± 1.0(C-D, P = 0.1771;C-CI, P = 0.0050)
34.1 ± 0.3 (C-D, P = 10⁻⁸;C-CI, P = 0.0382)

Average of the first series
41.6
90.0
29.5
51.8
33.7

Average of the second series
42.6
81.1
27.3
50.0
36.3

Average of the third series
45.8
75.9
33.5
55.1
36.1

Group CI (n = 7)
40.3 ± 1.2(CI-DI, P = 0.0226)
81.8 ± 2.1(CI-DI, P = 0.0107)
34.2 ± 2.0(CI-DI, P = 0.2647)
47.7 ± 1.2(CI-DI, P = 0.4680)
37.8 ± 1.2(CI-DI, P = 0.2633)

Average of the first series
40.6
83.2
30.0
46.6
40.6

Average of the second series
42.8
92.2
28.1
45.1
35.3

Average of the third series
37.3
75.1
39.0
51.2
38.7

Group D (n = 8)
28.0 ± 0.8(D-DI, P = 0.0031)
67,2 ± 4.0(D-DI, P = 0.1032)
21.4 ± 1.2(D-DI, P = 0.00065)
44.4 ± 5.1(D-DI, P = 0.8898)
22.3 ± 0.7(D-DI, P = 10⁻⁵)

Average of the first series
26.8
51.5
20.5
56.8
22.2

Average of the second series
29.4
72.6
19.4
32.7
25.0

Average of the third series
30.0
75.3
23.4
47.6
19.2

Group DI (n = 7)
33.9 ± 1.7
74.8 ± 1.3
29.5 ± 2.0
46.2 ± 1.7
37.9 ± 2.0

Average of the first series
33.9
75.9
25.4
50.2
34.7

Average of the second series
40.5
76.7
29.6
43.3
32.8

Average of the third series
31.7
70.8
33.2
45.6
40.2

(c) In picomole (pmol) of cAMP/min per milligram (mg) of membrane protein

Groups of Rats
hCG
PACAP-38

Group C (n = 8)
105 ± 4(C-D, P = 10⁻⁷;C-CI, P = 0.0270)
53 ± 3(C-D, P = 10⁻⁵;C-CI, P = 0.4720)

Average of the first series
127
44

Average of the second series
105
52

Average of the third series
95
58

Group CI (n = 7)
89 ± 5(CI-DI, P = 0.0039)
50 ± 2(CI-DI, P = 0.0007)

Average of the first series
110
50

Average of the second series
76
45

Average of the third series
84
69

Group D (n = 8)
40 ± 3(D-DI, P = 10⁻⁷)
29 ± 2(D-DI, P = 0.1024)

Average of the first series
40
25

Average of the second series
47
35

Average of the third series
36
30

Group DI (n = 7)
67 ± 2
34 ± 2

Average of the first series
66
29

Average of the second series
63
36

Average of the third series
71
40

Table 5: The inhibitory effects of hormones on forskolin-stimulated AC activity in the tissues of diabetic and control rats with and without I-I treatment. C: control animals; CI: control animals treated with intranasal insulin (I-I); D: diabetic animals with 210-day streptozotocin-induced diabetes mellitus of the type 1 (T1DM); DI: diabetic animals treated with I-I. The stimulating effect of forskolin (10⁻⁵ M) on the basal AC activity is taken as 100%. Values are the weighted mean ± weighted standard deviation of three individual experiments, each performed in triplicate.

(a) In percentages

Group C
Group CI
Group D
Group DI

Heart

Somatostatin
52 ± 3%(C-D, P = 10⁻⁸;C-CI, P = 0.7090)
55 ± 2%(CI-DI, P = 10⁻⁷)
88 ± 3%(D-DI, P = 0.0070)
78 ± 3%

Average of the first series
51
55
90
77

Average of the second series
59
57
83
83

Average of the third series
50
45
87
73

Noradrenaline
44 ± 2%(C-D, P = 10⁻⁶;C-CI, P = 0.0927)
49 ± 2%(CI-DI, P = 0.4005)
73 ± 3%(D-DI, P = 0.00015)
49 ± 4%

Average of the first series
44
51
63
52

Average of the second series
43
48
78
56

Average of the third series
42
42
69
43

Brain

Somatostatin
50 ± 3%(C-D, P = 0.0006;C-CI, P = 0.1043)
47 ± 3%(CI-DI, P = 0.0032)
66 ± 4%(D-DI, P = 0.0745)
58 ± 4%

Average of the first series
47
44
76
50

Average of the second series
52
52
62
67

Average of the third series
53
41
65
60

Noradrenaline
80 ± 3%(C-D, P = 0.1763;C-CI, P = 0.6663)
87 ± 3%(CI-DI, P = 0.9149)
93 ± 3%(D-DI, P = 0.4016)
84 ± 3%

Average of the first series
80
79
96
78

Average of the second series
92
86
84
84

Average of the third series
78
91
88
95

Bromocriptine
72 ± 3%(C-D, P = 0.0276;C-CI, P = 0.7451)
71 ± 4%(CI-DI, P = 0.1306)
81 ± 3%(D-DI, P = 0.4622)
81 ± 2%

Average of the first series
65
64
92
84

Average of the second series
68
76
74
78

Average of the third series
81
79
79
74

5-Nonyloxytryptamine
67 ± 4%(C-D, P = 10⁻⁶;C-CI, P = 0.2520)
62 ± 5%(CI-DI, P = 0.0446)
93 ± 3%(D-DI, P = 10⁻⁵)
70 ± 3%

Average of the first series
66
59
90
79

Average of the second series
63
66
91
68

Average of the third series
73
64
95
67

Testes

Somatostatin
64 ± 3%(C-D, P = 10⁻⁷;C-CI, P = 0.3465)
67 ± 4%(CI-DI, P = 10⁻⁶)
95 ± 3%(D-DI, P = 0.7882)
93 ± 3%

Average of the first series
65
73
104
107

Average of the second series
60
67
91
89

Average of the third series
64
59
96
93

(b) In picomole (pmol) of cAMP/min per milligram (mg) of membrane protein

Group C
Group CI
Group D
Group DI

Heart

Somatostatin
105.2 ± 5.7(C-D, P = 0.0039;C-CI, P = 0.8304)
111.8 ± 3.8(CI-DI, P = 0.0011)
127.2 ± 4.1(D-DI, P = 0.4273)
129.0 ± 5.1

Average of the first series
102.5
111.0
130.5
128.4

Average of the second series
119.3
115.0
119.9
137.8

Average of the third series
99.8
91.4
126.6
121.7

Noradrenaline
87.6 ± 4.1(C-D, P = 0.0080;C-CI, P = 0.0666)
99.7 ± 4.2(CI-DI, P = 0.0596)
105.4 ± 4.5(D-DI, P = 0.0110)
81.8 ± 6.6

Average of the first series
88.4
104.2
91.8
86.9

Average of the second series
87.1
98.1
112.6
93.0

Average of the third series
84.4
85.9
105.1
70.8

Brain

Somatostatin
82.8 ± 4.7(C-D, P = 0.0064;C-CI, P = 0.0721)
76.9 ± 5.0(CI-DI, P = 0.0203)
100.4 ± 5.8(D-DI, P = 0.0882)
89.4 ± 5.4

Average of the first series
78.6
71.6
115.5
76.5

Average of the second series
86.3
85.3
94.2
102.5

Average of the third series
87.4
67.8
98.8
92.3

Noradrenaline
132.4 ± 5.3(C-D, P = 0.6643;C-CI, P = 0.8534)
142.5 ± 5.5(CI-DI, P = 0.1950)
140.8 ± 4.4(D-DI, P = 0.4807)
128.7 ± 4.7

Average of the first series
133.4
129.6
145.9
119.3

Average of the second series
153.3
141.6
127.7
128.5

Average of the third series
129.5
148.7
133.8
145.9

Bromocriptine
120.3 ± 5.5(C-D, P = 0.4123;C-CI, P = 0.8973)
116.1 ± 7.0(CI-DI, P = 0.8306)
122.6 ± 4.0(D-DI, P = 0.5505)
124.6 ± 2.9

Average of the first series
108.5
105.0
139.8
129.0

Average of the second series
112.9
124.1
112.5
119.9

Average of the third series
134.5
129.6
120.6
113.7

5-Nonyloxytryptamine
111.7 ± 6.8(C-D, P = 0.000006;C-CI, P = 0.1797)
102.2 ± 8.1(CI-DI, P = 0.3600)
140.9 ± 3.9(D-DI, P = 10⁻⁵)
107.7 ± 4.9

Average of the first series
109.6
97.3
136.8
120.9

Average of the second series
105.1
108.2
138.8
104.0

Average of the third series
121.2
104.4
144.4
102.0

Testes

Somatostatin
26.3 ± 1.0(C-D, P = 10⁻⁷;C-CI, P = 0.6490)
25.6 ± 1.5(CI-DI, P = 10⁻⁴)
17.1 ± 0.6(D-DI, P = 0.0354)
21.5 ± 0.6

Average of the first series
26.8
27.9
18.8
24.5

Average of the second series
24.6
25.5
16.4
20.4

Average of the third series
26.2
22.4
17.3
21.4

(a)

(b)

Figure 1: The stimulating effects of (a) GppNHp and (b) forskolin on the basal AC activity in the heart, brain, and testes in diabetic and control rats treated with I-I or saline. C: control animals; CI: control animals treated with intranasal insulin (I-I); D: diabetic animals with 210-day streptozotocin-induced diabetes mellitus of the type 1 (T1DM); DI: diabetic animals treated with I-I. GppNHp and forskolin were taken at  M. Values are the weighted mean ± weighted standard deviation of three individual experiments, each performed in triplicate. * and *** denote the statistically significant difference between Groups C and D at and 0.001; ###, the same between Groups D and DI at ; &, &&, and &&&, the same between Groups CI and DI at , 0.01, and 0.001, respectively.

(a)

(b)

(c)

Figure 2: The stimulating effects of hormones on AC activity in (a) the heart, (b) brain, and (c) testes of diabetic and control rats with and without therapy by I-I. C: control animals; CI: control animals treated with intranasal insulin (I-I); D: diabetic animals with 210-day streptozotocin-induced diabetes mellitus of the type 1 (T1DM); DI: diabetic animals treated with I-I. Isoproterenol, noradrenaline, serotonin, EMD-386088, and dopamine were taken at 10⁻⁵ M, PACAP-38 at 10⁻⁷ M, and hCG at 10⁻⁸ M. Values are the weighted mean ± weighted standard deviation of three individual experiments, each performed in triplicate. ** and *** denote the statistically significant difference between Groups C and D at and 0.001; #, ##, and ###, the same between Groups D and DI at , 0.01, and 0.001; &, &&, and &&&, the same between Groups CI and DI at , 0.01, and 0.001, respectively.

Figure 3: The inhibitory effects of hormones on forskolin-stimulated AC activity in the tissues of diabetic and control rats with and without I-I treatment. C: control animals; CI: control animals treated with intranasal insulin (I-I); D: diabetic animals with 210-day streptozotocin-induced diabetes mellitus of the type 1 (T1DM); DI: diabetic animals treated with I-I; 1, 3, and 7: somatostatin (10⁻⁶ M) in the heart, brain, and testes, respectively; 2 and 4: noradrenaline (10⁻⁵ M) in the heart and brain, respectively; 5: bromocriptine (10⁻⁵ M) in the brain; 6: 5-nonyloxytryptamine (10⁻⁵ M) in the brain. The stimulating effect of forskolin (10⁻⁵ M) on the basal AC activity is taken as 100%. Values are the weighted mean ± weighted standard deviation of three individual experiments, each performed in triplicate. * and *** denote the statistically significant difference between Groups C and D at and 0.001; #, ##, and ###, the same between Groups D and DI at , 0.01, and 0.001; &, &&, and &&&, the same between Groups CI and DI at , 0.01, and 0.001, respectively.

Dataset Availability

The dataset associated with this Dataset Paper is dedicated to the public domain using the CC0 waiver and is available at http://dx.doi.org/10.7167/2013/698435/dataset.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgments

This work was supported by the Ministry of Education and Science of Russian Federation (Project no. 8486) and by RFBR (Grant nos. 12-04-00434 and 12-04-32034). The authors are grateful to Inga Menina for linguistic assistance.

References

M. C. Stiles and E. R. Seaquist, “Cerebral structural and functional changes in type 1 diabetes,” Minerva Medica, vol. 101, no. 2, pp. 105–114, 2010.

C. E. Tabit, W. B. Chung, N. M. Hamburg, and J. A. Vita, “Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications,” Reviews in Endocrine and Metabolic Disorders, vol. 11, no. 1, pp. 61–74, 2010.

A. O. Shpakov, O. V. Chistiakova, K. V. Derkach, and V. M. Bondareva, “Hormonal signaling systems of the brain in diabetes mellitus,” in Neurodegenerative Diseases—Processes, Prevention, Protection and Monitoring, R. C. C. Chang, Ed., pp. 349–386, Intech Open Access Publisher, Rijeka, Croatia, 2011.

V. M. Altan, E. Arioglu, S. Guner, and A. T. Ozcelikay, “The influence of diabetes on cardiac β-adrenoceptor subtypes,” Heart Failure Reviews, vol. 12, no. 1, pp. 58–65, 2007.

A. Wichelhaus, M. Russ, S. Petersen, and J. Eckel, “G protein expression and adenylate cyclase regulation in ventricular cardiomyocytes from STZ-diabetic rats,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 267, no. 2, pp. H548–H555, 1994.

S. Gando, Y. Hattori, Y. Akaishi, J. Nishihira, and M. Kanno, “Impaired contractile response to beta adrenoceptor stimulation in diabetic rat hearts: alterations in beta adrenoceptors-G protein-adenylate cyclase system and phospholamban phosphorylation,” Journal of Pharmacology and Experimental Therapeutics, vol. 282, no. 1, pp. 475–484, 1997.

L. P. Weber and K. M. Macleod, “Influence of streptozotocin diabetes on the α-1 adrenoceptor and associated G proteins in rat arteries,” Journal of Pharmacology and Experimental Therapeutics, vol. 283, no. 3, pp. 1469–1478, 1997.

A. O. Shpakov, L. A. Kuznetsova, S. A. Plesneva, I. A. Gur'ianov, and M. N. Pertseva, “Molecular causes of changes in sensitivity of adenylyl cyclase signaling system to biogenic amines in the heart muscle during experimental streptozotocin diabetes,” Tsitologiia., vol. 47, no. 6, pp. 540–548, 2005.

A. O. Shpakov, L. A. Kuznetsova, S. A. Plesneva et al., “Functional defects in adenylyl cyclase signaling mechanisms of insulin and relaxin in skeletal muscles of rat with streptozotocin type 1 diabetes,” Central European Journal of Biology, vol. 1, no. 4, pp. 530–544, 2006.

A. O. Shpakov, V. M. Bondareva, and O. V. Chistyakova, “Functional state of adenylyl cyclase signaling system in reproductive tissues of rats with experimental type 1 diabetes,” Tsitologiya, vol. 52, no. 2, pp. 177–183, 2010.

U. D. Dinçer, K. R. Bidasee, S. Güner, A. Tay, A. T. Özçelikay, and V. M. Altan, “The effect of diabetes on expression of β1-, β2-, and β3-adrenoreceptors in rat hearts,” Diabetes, vol. 50, no. 2, pp. 455–461, 2001.

B. Savitha, B. Joseph, T. P. Kumar, and C. S. Paulose, “Acetylcholine and muscarinic receptor function in cerebral cortex of diabetic young and old male wistar rats and the role of muscarinic receptors in calcium release from pancreatic islets,” Biogerontology, vol. 11, no. 2, pp. 151–166, 2010.

R. I. Henkin, “Intranasal insulin: from nose to brain,” Nutrition, vol. 26, no. 6, pp. 624–633, 2010.

C. Benedict, W. H. Frey, H. B. Schiöth, B. Schultes, J. Born, and M. Hallschmid, “Intranasal insulin as a therapeutic option in the treatment of cognitive impairments,” Experimental Gerontology, vol. 46, no. 2-3, pp. 112–115, 2011.

U. Stockhorst, D. de Fries, H. J. Steingrueber, and W. A. Scherbaum, “Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans,” Physiology and Behavior, vol. 83, no. 1, pp. 47–54, 2004.

A. O. Shpakov, O. V. Chistyakova, K. V. Derkach, I. V. Moiseyuk, and V. M. Bondareva, “Intranasal insulin affects adenylyl cyclase system in rat tissues in neonatal diabetes,” Central European Journal of Biology, vol. 7, no. 1, pp. 33–47, 2012.

E. S. Khafagy, M. Morishita, Y. Onuki, and K. Takayama, “Current challenges in non-invasive insulin delivery systems: a comparative review,” Advanced Drug Delivery Reviews, vol. 59, no. 15, pp. 1521–1546, 2007.

G. J. Francis, J. A. Martinez, W. Q. Liu et al., “Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy,” Brain, vol. 131, no. 12, pp. 3311–3334, 2008.

“Guidelines for the treatment of animals in behavior research and teaching,” Animal Behaviour, vol. 71, no. 1, pp. 245–253, 2006.

R. G. Thorne, G. J. Pronk, V. Padmanabhan, and W. H. Frey II, “Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration,” Neuroscience, vol. 127, no. 2, pp. 481–496, 2004.

S. P. Baker and L. T. Potter, “A minor component of the binding of [³H]guanyl-5′-yl imidodiphosphate to cardiac membranes associated with the activation of adenylate cyclase,” The Journal of Biological Chemistry, vol. 256, no. 15, pp. 7925–7931, 1981.

A. O. Shpakov, E. A. Shpakova, I. I. Tarasenko, K. V. Derkach, and G. P. Vlasov, “The peptides mimicking the third intracellular loop of 5-hydroxytryptamine receptors of the types 1B and 6 selectively activate G proteins and receptor-specifically inhibit serotonin signaling via the adenylyl cyclase system,” International Journal of Peptide Research and Therapeutics, vol. 16, no. 2, pp. 95–105, 2010.

A. O. Shpakov, E. A. Shpakova, I. I. Tarasenko et al., “The influence of peptides corresponding to the third intracellular loop of luteinizing hormone receptor on basal and hormone-stimulated activity of the adenylyl cyclase signaling system,” Global Journal of Biochemistry, vol. 2, no. 1, pp. 59–73, 2011.

O. V. Chistyakova, V. M. Bondareva, V. N. Shipilov, I. B. Sukhov, and A. O. Shpakov, “A positive effect of intranasal insulin on spatial memory in rats with neonatal diabetes mellitus,” Endocrinology Studies, vol. 1, article e16, 2011.

A. O. Shpakov, L. A. Kuznetsova, S. A. Plesneva, I. A. Gur'ianov, G. P. Vlasov, and M. N. Pertseva, “Identifications of disturbances in hormone-sensitive adenylyl cyclase system in the tissues of rats with types 1 and 2 diabetes using functional probes and synthetic peptides,” Tekhnologii Zhivykh Sistem, vol. 4, pp. 96–108, 2005.

K. R. Bidasee, H. Zheng, C. H. Shao, S. K. Parbhu, G. J. Rozanski, and K. P. Patel, “Exercise training initiated after the onset of diabetes preserves myocardial function: effects on expression of β-adrenoceptors,” Journal of Applied Physiology, vol. 105, no. 3, pp. 907–914, 2008.

U. D. Dinçer, A. Onay, N. Ari, A. T. Özçelikay, and V. M. Altan, “The effects of diabetes on β-adrenoceptor mediated responsiveness of human and rat atria,” Diabetes Research and Clinical Practice, vol. 40, no. 2, pp. 113–122, 1998.

B. Marcos, M. García-Alloza, F. J. Gil-Bea et al., “Involvement of an altered 5-HT6 receptor function in behavioral symptoms of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 14, no. 1, pp. 43–50, 2008.

K. Tully and V. Y. Bolshakov, “Emotional enhancement of memory: how norepinephrine enables synaptic plasticity,” Molecular Brain, vol. 3, no. 1, pp. 15–23, 2010.

A. D. Mooradian and P. J. Scarpace, “β-Adrenergic receptor activity of cerebral microvessels in experimental diabetes mellitus,” Brain Research, vol. 583, no. 1-2, pp. 155–160, 1992.

D. Reglodi, P. Kiss, A. Lubics, and A. Tamas, “Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo,” Current Pharmaceutical Design, vol. 17, no. 10, pp. 962–972, 2011.

C. Benedict, M. Hallschmid, A. Hatke et al., “Intranasal insulin improves memory in humans,” Psychoneuroendocrinology, vol. 29, no. 10, pp. 1326–1334, 2004.

M. P. Abbracchio, M. Di Luca, A. M. Di Giulio, F. Cattabeni, B. Tenconi, and A. Gorio, “Denervation and hyperinnervation in the nervous system of diabetic animals: III. Functional alterations of G proteins in diabetic encephalopathy,” Journal of Neuroscience Research, vol. 24, no. 4, pp. 517–523, 1989.

R. Robinson, A. Krishnakumar, and C. S. Paulose, “Enhanced dopamine D1 and D2 receptor gene expression in the hippocampus of hypoglycaemic and diabetic rats,” Cellular and Molecular Neurobiology, vol. 29, no. 3, pp. 365–372, 2009.

M. J. Carmena, C. Clemente, L. G. Guijarro, and J. C. Prieto, “The effect of streptozotocin diabetes on the vasoactive intestinal peptide receptor/effector system in membranes from rat ventral prostate,” Endocrinology, vol. 131, no. 4, pp. 1993–1998, 1992.

M. S. Rodriguez-Pena, L. G. Guijarro, M. G. Juarranz et al., “Analysis of vasoactive intestinal peptide receptors and the G protein regulation of adenylyl cyclase in seminal vesicle membranes from streptozotocin-diabetic rats,” Cellular Signalling, vol. 6, no. 2, pp. 147–156, 1994.

J. X. Li and C. P. France, “Food restriction and streptozotocin treatment decrease 5-HT1A and 5-HT2A receptor-mediated behavioral effects in rats,” Behavioural Pharmacology, vol. 19, no. 4, pp. 292–297, 2008.

L. Lanfumey and M. Hamon, “5-HT1 receptors,” Current Drug Targets: CNS and Neurological Disorders, vol. 3, no. 1, pp. 1–10, 2004.

J. F. Bruno, Y. Xu, J. Song, and M. Berelowitz, “Pituitary and hypothalamic somatostatin receptor subtype messenger ribonucleic acid expression in the food-deprived and diabetic rat,” Endocrinology, vol. 135, no. 5, pp. 1787–1792, 1994.

S. Gao, Y. B. Oh, A. Shah, W. H. Park, and S. H. Kim, “Suppression of ANP secretion by somatostatin through somatostatin receptor type 2,” Peptides, vol. 32, no. 6, pp. 1179–1186, 2011.

J. T. Yue, E. Burdett, D. H. Coy, A. Giacca, S. Efendic, and M. Vranic, “Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats,” Diabetes, vol. 61, no. 1, pp. 197–207, 2012.

G. M. Portela-Gomes, L. Grimelius, P. Westermark, and M. Stridsberg, “Somatostatin receptor subtypes in human type 2 diabetic islets,” Pancreas, vol. 39, no. 6, pp. 836–842, 2010.